- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00491959
The Application of Oral Mucosal Epithelial Cell Sheets Cultivated on Amino Membrane in Patients Suffering From Corneal Stem Cell Insufficiency or Symblepharon.
May 3, 2010 updated by: National Taiwan University Hospital
Phase 1 Study of Oral Mucosal Epithelial Cell Sheets in Patients Suffering From Corneal Stem Cell Insufficiency or Symblepharon
Since cultivated autologous oral mucosal epithelial sheets on amniotic membrane have been reported to have good clinical results in treating patients with ocular surface disorders in both human or animal studies, and such technique has not been used in our hospital, the main purpose of this study is to use these cell sheets to treat patients with severe surface disorders, which include limbal insufficiency induced corneal surface problem, and symblepharon caused by severe conjunctival epithelial insufficiency.
We will first choose patients who meet the surgical criteria, and these patients need to receive dental examination three months before surgery.
Two weeks before transplantation, the oral mucosa tissue will be obtained by a dentist and the oral mucosal epithelial cell sheets will be cultivated on amniotic membrane until reaching confluency and stratification.
During the transplantation surgery, the abnormal fibrovascular tissues on the ocular surface will be removed.
The areas of symblepharon will also be released.
The cultivated oral mucosal cell sheets will be transplanted on the denuded corneal surface or the scleral surface of the symblepharon area.
Therapeutic contact lenses will be applied after surgery.
After operation, the patients will be admitted for about two weeks.
After discharge, the patients need to receive regular follow up weekly during the first two months, followed by biweekly follow up until postoperative 6 months.
Afterward, the patients need to receive monthly follow up until postoperative 2 years.
During the follow up, the data of the patients' visual acuity, intraocular pressure, slit lamp biomicroscopic findings, and in vivo confocal microscopic data will be obtained.
The project plans to start from July 1st 2007 until June 30th 2010.
We plan to enroll totally 20 patients.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Cultivated autologous oral mucosal epithelial sheets on amniotic membrane have been reported to have good clinical results in treating patients with ocular surface disorders in both human or animal studies, and such technique has not been used in our hospital, the main purpose of this study is to use these cell sheets to treat patients with severe surface disorders, which include limbal insufficiency induced corneal surface problem, and symblepharon caused by severe conjunctival epithelial insufficiency.
We will first choose patients who meet the surgical criteria, and these patients need to receive dental examination three months before surgery.
Two weeks before transplantation, the oral mucosa tissue will be obtained by a dentist and the oral mucosal epithelial cell sheets will be cultivated on amniotic membrane until reaching confluency and stratification.
During the transplantation surgery, the abnormal fibrovascular tissues on the ocular surface will be removed.
The areas of symblepharon will also be released.
The cultivated oral mucosal cell sheets will be transplanted on the denuded corneal surface or the scleral surface of the symblepharon area.
Therapeutic contact lenses will be applied after surgery.
After operation, the patients will be admitted for about two weeks.
After discharge, the patients need to receive regular follow up weekly during the first two months, followed by biweekly follow up until postoperative 6 months.
Afterward, the patients need to receive monthly follow up until postoperative 2 years.
During the follow up, the data of the patients' visual acuity, intraocular pressure, slit lamp biomicroscopic findings, and in vivo confocal microscopic data will be obtained.
The project plans to start from July 1st 2007 until June 30th 2010.
We plan to enroll totally 20 patients.
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan, 10047
- National Taiwan University Hospital, department of Ophthalmology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- patient with bilateral limbal insufficiency
Exclusion Criteria:
- ocular diseases other than limbal insufficiency glaucoma diseases of retina or optic nerve
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
condition of ocular surface
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Chair: Fung-Rong Hu, MD, National Taiwan University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2007
Primary Completion (Actual)
April 1, 2010
Study Completion (Actual)
April 1, 2010
Study Registration Dates
First Submitted
June 23, 2007
First Submitted That Met QC Criteria
June 23, 2007
First Posted (Estimate)
June 26, 2007
Study Record Updates
Last Update Posted (Estimate)
May 4, 2010
Last Update Submitted That Met QC Criteria
May 3, 2010
Last Verified
April 1, 2010
More Information
Terms related to this study
Other Study ID Numbers
- 200701043D
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Symblepharon
-
Federal University of São PauloUnknown
-
Federal University of São PauloCompletedDry Eye | Transplantation | Ocular Surface Disease | SymblepharonBrazil
Clinical Trials on Cultured oral mucosa cell sheet transplantation
-
CliPS Co., LtdCompletedLimbus Corneae Insufficiency Syndrome | Limbus CorneaeKorea, Republic of
-
He Eye HospitalUnknown
-
CellSeed Inc.CompletedSuperficial Esophageal CancerJapan
-
Siriraj HospitalOsaka UniversityCompletedLimbal Stem-cell DeficiencyThailand
-
Royan InstituteHazrat Fatemeh HospitalCompletedEpidermolysis Bullosa With Mitten HandsIran, Islamic Republic of
-
Seoul National University HospitalMinistry of Health & Welfare, KoreaAvailableLimbal Stem Cell Deficiency | Ocular Cicatricial Pemphigoid | Stevens-johnson Syndrome | Chemical BurnKorea, Republic of
-
Virginia Commonwealth UniversityTerminatedMalignant Neoplasm | Leukemia, Not Otherwise SpecifiedUnited States
-
Chang Gung Memorial HospitalRecruiting
-
Johannes Gutenberg University MainzRoche Pharma AGCompleted
-
Federico II UniversityWithdrawnChronic Hepatitis CItaly